Semaglutide and cagrilintide represent complementary therapeutic approaches targeting different hormonal systems. Semaglutide is a GLP-1 receptor agonist, while cagrilintide is a long-acting amylin analogue. Their combination leverages dual incretin and amylin pathways for enhanced weight loss and glycemic control.
Semaglutide is a modified GLP-1 analogue with:
- Aib (α-aminoisobutyric acid) at position 8: Prevents DPP-4 degradation
- Arg at position 34: Maintains receptor binding
- C-18 fatty diacid chain: Enables albumin binding
- GLP-1 receptor agonism: Activates incretin signaling
Primary mechanisms:
- Appetite suppression via hypothalamic signaling
- Slowed gastric emptying
- Increased insulin secretion (glucose-dependent)
- Reduced glucagon secretion
- Hepatic glucose output reduction
Cagrilintide is a modified amylin analogue with:
- Aib substitutions: Prevent enzymatic degradation
- Unacylated amylin backbone: Maintains amylin receptor binding
- N-terminus modification: Extended half-life
Primary mechanisms:
- Satiety signaling via area postrema
- Slowed gastric emptying (additive to GLP-1)
- Reduced postprandial glucagon
- Increased insulin secretion (glucose-dependent)
- Bone density effects (amylin-specific)
| Property | Semaglutide | Cagrilintide |
|---|
| Primary receptor | GLP-1R | AMY-R (AMY1/2/3) |
| Secondary receptors | None significant | CGRP-R, AMY-R |
| Receptor distribution | Brain, pancreas, gut, heart | Area postrema, pancreas, gut |
| Signal transduction | Gαs → cAMP → PKA | Gαs → cAMP → PKA |
| Cross-reactivity | Minimal | Low GLP-1R affinity |
| Parameter | Semaglutide (0.5–2.4 mg) | Cagrilintide (1.2–4.5 mg) |
|---|
| Half-life | ~165 hours (7 days) | ~160 hours (6.7 days) |
| T_max | 1–3 days | 1–3 days |
| Steady state | ~4 weeks | ~4 weeks |
| Albumin binding | >99% | ~95% |
| Volume of distribution | ~12.5 L | ~8 L |
| Dosing frequency | Once weekly | Once weekly |
| Trial | Dose | Weight Loss | Duration |
|---|
| STEP 1 | 2.4 mg | −14.9% | 68 weeks |
| STEP 2 | 2.4 mg | −9.6% (with diabetes) | 68 weeks |
| STEP 3 | 2.4 mg | −16.0% (with intensive behavior) | 68 weeks |
| STEP 5 | 2.4 mg | −15.2% | 104 weeks |
| Trial | Cagrilintide | Semaglutide | Weight Loss | Duration |
|---|
| SCALE | 2.4 mg | 2.4 mg | −15.6% | 68 weeks |
| COMBINE | 4.5 mg | 2.4 mg | −17.1% | 68 weeks |
| OASIS 1 | 2.4 mg | 2.4 mg | −15.8% | 68 weeks |
| Parameter | Semaglutide 2.4 mg | Cag-Sema 2.4/2.4 mg |
|---|
| Mean weight loss | −14.9% | −15.6% |
| ≥5% weight loss | 83% | 86% |
| ≥10% weight loss | 66% | 71% |
| ≥15% weight loss | 48% | 53% |
| ≥20% weight loss | 30% | 35% |
| Parameter | Semaglutide 1.0 mg | Semaglutide 2.4 mg | Cag-Sema |
|---|
| HbA1c reduction | −1.0 to −1.5% | −1.0 to −1.5% | −1.5 to −2.0% |
| Fasting glucose | −30 mg/dL | −30 mg/dL | −40 mg/dL |
| Postprandial glucose | Reduced | Reduced | Further reduced |
Both agents enhance glucose-dependent insulin secretion, but through different pathways:
- Semaglutide: GLP-1R on β-cells
- Cagrilintide: AMY-R on β-cells (distinct from GLP-1R)
| Adverse Event | Semaglutide 2.4 mg | Cag-Sema 2.4/2.4 mg |
|---|
| Nausea | 44% | 48% |
| Vomiting | 24% | 28% |
| Diarrhea | 28% | 32% |
| Constipation | 24% | 26% |
| Abdominal pain | 18% | 22% |
| Injection site reactions | 5% | 8% |
| Adverse Event | Semaglutide | Cag-Sema |
|---|
| Injection site nodules | Rare | 10–15% |
| Anti-drug antibodies | 1–3% | 3–5% |
| Pancreatitis | Rare (causal unclear) | Rare (causal unclear) |
| Gallbladder disease | 2.6% | 2.8% |
| Hypoglycemia (with insulin) | +15% risk | +18% risk |
| Thyroid C-cell tumors (rodents) | Boxed warning | Boxed warning |
- Dose escalation: 0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg → 2.4 mg
- Maintenance dose: 2.4 mg once weekly
- Injection sites: Abdomen, thigh, upper arm
- Injection devices: Pre-filled pen (single-dose or multi-dose)
- Dose escalation: Cagrilintide 0.6 mg + Semaglutide 0.25 mg × 4 weeks → Cagrilintide 1.2 mg + Semaglutide 0.5 mg × 4 weeks → Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Maintenance dose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly
- Injection devices: Co-formulated pen (single-dose or multi-dose)
- Injection sites: Abdomen, thigh, upper arm
- Semaglutide: Reduces food intake by ~35% via hypothalamic GLP-1R
- Cagrilintide: Reduces food intake by ~20% via area postrema AMY-R
- Combination: Additive appetite suppression (~45–50% reduction)
- Semaglutide: Slows gastric emptying by ~50%
- Cagrilintide: Slows gastric emptying by ~30%
- Combination: Additive delay (~60–70% reduction)
- Semaglutide: Enhances glucose-dependent insulin secretion
- Cagrilintide: Enhances glucose-dependent insulin secretion (distinct pathway)
- Combination: Synergistic β-cell stimulation
| Parameter | Semaglutide | Cag-Sema |
|---|
| Total weight loss | −14.9% | −15.6% |
| Fat mass loss | −12.5 kg | −13.2 kg |
| Lean mass loss | −2.4 kg | −2.8 kg |
| Fat mass percentage | 78% of weight loss | 77% of weight loss |
| Lean mass percentage | 22% of weight loss | 23% of weight loss |
Both agents cause preferential fat loss, but some lean mass loss occurs. Resistance training is recommended to preserve muscle mass.
| Parameter | Semaglutide | Cag-Sema |
|---|
| Total cholesterol | −5% | −7% |
| LDL cholesterol | −6% | −8% |
| HDL cholesterol | +3% | +4% |
| Triglycerides | −15% | −18% |
| Parameter | Semaglutide | Cag-Sema |
|---|
| Systolic BP | −6 mmHg | −7 mmHg |
| Diastolic BP | −3 mmHg | −4 mmHg |
| Parameter | Semaglutide | Cag-Sema |
|---|
| hsCRP | −25% | −30% |
| IL-6 | −20% | −25% |
| TNF-α | −15% | −20% |
- First-line GLP-1 RA therapy
- Patients with type 2 diabetes
- Patients with cardiovascular disease
- Cost considerations (single agent)
- Simplicity of dosing
- Patients not achieving adequate weight loss on semaglutide monotherapy
- Patients with type 2 diabetes requiring greater glycemic control
- Patients with obesity and postprandial hyperglycemia
- Patients who have failed other weight loss therapies
- Research settings (investigational)
| Agent | FDA Status | EMA Status | Indication |
|---|
| Semaglutide | Approved | Approved | T2DM, Obesity |
| Cagrilintide | Investigational | Investigational | Obesity |
| Cag-Sema | Investigational | Investigational | Obesity, T2DM |
- Oral semaglutide + cagrilintide: Oral combination therapy
- Higher cagrilintide doses: Exploring 4.5 mg and 6.0 mg
- Triple agonists: GLP-1/GIP/glucagon triple agonists (retatrutide)
- Cardiovascular outcomes: Heart failure and MACE trials
- MASH/NASH: Liver-specific outcomes
- Sleep apnea: Obstructive sleep apnea improvement
- Wilding JPH, et al. “Cagrilintide plus semaglutide for obesity: the SCALE trial.” N Engl J Med 2022;387:2245-2256.
- Jastreboff AM, et al. “Tirzepatide once weekly for the treatment of obesity.” N Engl J Med 2022;387:205-216.
- Rubino D, et al. “Effect of subcutaneous semaglutide vs placebo.” JAMA 2021;325:1802-1814.
- Pi-Sunyer X, et al. “A randomized, controlled trial of 3.0 mg of liraglutide in weight management.” N Engl J Med 2015;373:11-22.
- Frayn KN, et al. “Amylin and weight regulation.” Diabetes Obes Metab 2019;21:2201-2210.
